Vascular Disease Topics
The On-Topic Netowork

Vascular Disease > Heart attack or “myocardial infarction”

The following information is about Heart attack or “myocardial infarction”.

Heart attack or “myocardial infarction” Defined

This definition is in context to Vascular Disease. See more contextual defintions for Heart attack or “myocardial infarction”.


YourHealth: Know your arteries for a healthier heart

Published September 6, 2008, 5:48 pm, The New Straits Times

THIS month, the World Heart Federation will be celebrating World Heart Day 2008 with the theme “Know Your Risk".

Full Story


Positive Phase II Results For FX06 - Fibrin-Derived Peptide For The Treatment Of Reperfusion Injury In Myocardial ...

Published September 4, 2008, 7:11 am, Medical News Today

Fibrex Medical, a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The results will be presented at the ESC Congress today in Munich, Germany.

Full Story


New Method For Early Detection Of A Heart Attack

Published September 4, 2008, 5:10 am, Medical News Today

The sooner an individual who has had a heart attack is treated, the better their chance of survival and the less permanent damage is done to their heart. So, Robert Gerszten and colleagues, at Massachusetts General Hospital, Charlestown, have developed a new method for early detection of a heart attack.

Full Story


Fibrin Derived Peptide FX06 Reduces Cardiac Reperfusion Injury

Published September 3, 2008, 3:11 am, Medical News Today

Data presented at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack. While reperfusion is well established as a standard of care, it paradoxically causes additional damage to heart muscle in patients surviving from these attacks a phenomenon termed "reperfusion injury".

Full Story


Fibrex medical reports positive phase II results for peptide for the treatment of reperfusion injury

Published September 2, 2008, 4:25 pm, News-Medical-Net

Fibrex Medical has announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The results will be presented at the ESC Congress today in Munich, Germany.

Full Story


Fibrin-derived peptide FX06 reduces cardiac reperfusion injury

Published September 2, 2008, 8:26 am, EurekAlert!

( European Society of Cardiology ) Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack. While reperfusion is well established as a standard of care, it paradoxically causes additional damage to heart muscle in patients surviving from these attacks ...

Full Story


Fibrex Medical Report Positive Phase II Results for FX06

Published September 2, 2008, 3:30 am, Business Wire via Yahoo! Finance

CAMBRIDGE, Mass. & VIENNA, Austria----Fibrex Medical, a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, today announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury – the damage to heart muscle that results from remedial treatment following a heart attack.

Full Story


Fibrin-derived peptide FX06 reduces cardiac reperfusion injury

Published September 2, 2008, 3:25 am, News-Medical-Net

Data presented today at the European Society of Cardiology Congress demonstrates the effectiveness of a peptide called FX06 in preventing cardiac damage resulting from treatment following a heart attack.

Full Story


Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ...

Published September 1, 2008, 6:09 am, Medical News Today

The results of the TRANSCEND® trial demonstrate that Micardis® 80mg (telmisartan) reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving best standard of care (p=0.

Full Story


First Landmark ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces the Risk of Cardiovascular Death, ...

Published August 31, 2008, 8:04 pm, Thaipr.net

- TRANSCEND(R), Parallel Trial to ONTARGET(R), Confirms Long-Term Protective Benefits and Excellent Tolerability Profile of Telmisartan 80mg(1) on Top of Current Best Standard of Care The r

Full Story


Are you looking for additional Vascular Disease > Heart Attack Or “myocardial Infarction” news? Try our new "Heart Attack Or “myocardial Infarction” News Focus" area.

Social bookmarks are not available at the moment.

If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Heart attack or “myocardial infarction”. If you would like to find related tags we recommend Tag Patterns > Heart attack or “myocardial infarction”

Off-site Heart Attack Or “myocardial Infarction” Research Links

If you still need additional information on Heart Attack Or “myocardial Infarction” then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Vascular Disease

If you know the Vascular Disease Term Name use the links below to quickly jump to your desired focus.



Bookmark Us

The On Topic Network

This website is part of The On Topic Network.

Thank You

Vascular-Disease.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.

Best Viewed With

License

Creative Commons License This work is licensed under Creative Commons.




Powered by Odin Assemble 2.5a